Medincell, a pharmaceutical company focused on long-acting injectables, has announced it has secured $140.7M in new funding from investors. This substantial capital infusion marks a significant development for the commercial-stage company, which is dedicated to improving global health through innovative therapeutic options and its mission of "Better Medicine for All."
The company specializes in developing a portfolio of long-acting injectables across various therapeutic areas. At the core of its approach is the proprietary BEPO® technology, which is designed to enhance patient compliance, improve treatment effectiveness and accessibility, and reduce the environmental footprint of medications. Medincell actively collaborates with tier-one pharmaceutical companies and foundations, leveraging these partnerships to advance its goal of delivering new therapeutic options globally.
This funding round is poised to significantly accelerate Medincell's strategic objectives as a commercial-stage entity. The $140.7M raised will be instrumental in supporting the company's ambitious growth initiatives, including the expansion of its long-acting injectable portfolio and the advancement of its robust pipeline. This investment underscores strong confidence in Medincell's innovative technology and its potential to address critical, unmet needs in patient care and global health on a broader scale.
Medincell's business model is built on the principle of fair sharing of value created with all its employees, with the sustainability of its operations being an essential condition for achieving its long-term objectives. With this new capital, the company is well-positioned to further its mission to contribute to the improvement and protection of health populations worldwide, driving continued innovation and expanding its impact in the pharmaceutical sector.
.png&w=3840&q=75)
